Learn the GLP Study Director; responsibilities, qualifications, QAU relationship, protocol duties and role in multi-site studies.
A Good Laboratory Practice (GLP) Study Director leads the technical conduct of a nonclinical laboratory study and serves as its single point of study control. The role covers study oversight, data review, protocol compliance, reporting, and transfer of records to the archive. Under FDA GLP regulations, the Study Director is responsible for the study’s interpretation, analysis, documentation, and reporting.
This is a GLP role for nonclinical studies, such as toxicology or pharmacology safety studies. It is distinct from cGMP responsibilities for pharmaceutical manufacturing and batch release. https://iampharmacist.com/pfas/
Key takeaways
- The Study Director is designated before the study begins and oversees its overall technical conduct.
- The protocol must be approved and followed; changes require documentation, reasons, the Study Director’s signature, and a date.
- The Study Director ensures study data are accurately recorded and verified, and that significant unforeseen circumstances are documented with corrective action.
- The Quality Assurance Unit (QAU) monitors independently; it does not conduct or direct the study.
- GLP rules require suitable education, training, and experience, but do not specify one mandatory degree.
Core responsibilities of a GLP Study Director
Protocol and study control
The Study Director ensures the study follows its approved written protocol. For FDA-regulated GLP studies, the protocol records sponsor approval and the Study Director’s dated signature. Changes or revisions to an approved protocol must be documented with the reason, signed by the Study Director, dated, and kept with the protocol.
A protocol amendment is different from an unexpected deviation during study conduct. The Study Director evaluates circumstances that could affect study quality or integrity, ensures corrective action is taken, and documents it. Facility procedures should explain how personnel report and record deviations. Related pharmaceutical SOP guidance can help explain how controlled procedures support consistent study work.
Data review and GLP compliance
The Study Director ensures experimental data—including unanticipated responses of the test system—are accurately recorded and verified. They also ensure applicable GLP requirements are followed and that the test system matches the protocol. These duties make the Study Director accountable for coordinating the evidence and decisions needed to understand how the study was performed.
In practical terms, if a toxicology study records an unexpected clinical observation in an animal, the responsible staff document it promptly. The Study Director assesses whether it affects study conduct or interpretation, determines any needed corrective action, and ensures the issue is reflected appropriately in study records and reporting.
Final report and archiving
The Study Director signs and dates the final report. The report summarizes the study methods, results, analysis, and conclusions, identifies circumstances that may have affected data quality or integrity, and includes the QAU statement. The Study Director also ensures raw data, documentation, protocols, specimens, and final reports are transferred to the archive during or at the close of the study.
Study Director, QAU, and Principal Investigator
| Role | Main function | Responsibility and boundary |
|---|---|---|
| Study Director | Overall study control | Oversees technical conduct, data review, protocol compliance, interpretation, and reporting. |
| Quality Assurance Unit | Independent monitoring | Monitors GLP compliance, inspects the study at intervals adequate to assure its integrity, reports issues, and reviews the final report. It must remain independent of personnel directing or conducting the study. |
| Principal Investigator (PI) | Delegated phase at a test site | In OECD multi-site studies, manages a defined delegated phase and communicates relevant progress and records to the Study Director. The Study Director retains overall study control. |
The QAU and Study Director have separate functions. The QAU must be independent from those directing and conducting the study. It maintains protocol copies, inspects the study, reports significant problems to the Study Director and management, and reviews whether the final report accurately reflects the methods and raw data. Its signed statement records inspection dates and findings reported.
A facility may use a pre-study QAU protocol review as a control in its procedures, but the QAU does not formally approve the protocol under FDA Part 58. The protocol records sponsor approval and the Study Director’s dated signature. For multi-site studies, OECD guidance describes the PI as responsible for a delegated phase, while the Study Director remains responsible for the whole study.
Qualifications and training
FDA GLP regulations require the Study Director to be a scientist or other professional with appropriate education, training, and experience—or an appropriate combination of these—to perform the role. The testing facility must maintain a current summary of each relevant person’s training and experience and a job description. The regulation does not require a specific bachelor’s, master’s, or doctoral degree.
A facility should select someone whose scientific background and practical experience fit the study type and methods. For a pharmaceutical toxicology study, relevant expertise may include toxicology, pharmacology, biology, chemistry, or another suitable discipline. Leadership, clear communication, and the ability to evaluate study data are useful competencies. Keep training records current under facility procedures; Part 58 does not set a universal retraining interval.
Practical oversight checklist
Before and during a study, confirm that:
- A qualified Study Director has been designated before initiation.
- The approved protocol and any amendments are current, signed, dated, and available.
- Study staff understand their assigned tasks and escalation route.
- Experimental data are recorded and verified, including unexpected observations.
- Deviations and unforeseen circumstances are assessed and documented.
- The QAU can perform independent monitoring and report findings.
- Study records and specimens are transferred to the archive as required.
Frequently asked questions
1. What is a GLP Study Director?
The Study Director is the professional with overall responsibility for the technical conduct, interpretation, analysis, documentation, and reporting of a nonclinical laboratory study.
2. When must a Study Director be appointed?
Testing facility management must designate a Study Director before the study is initiated.
3. Does the Study Director need a PhD?
No specific degree is named in 21 CFR Part 58. The person must have appropriate education, training, and experience—or a suitable combination—to perform the assigned role.
4. Who approves the GLP study protocol?
The protocol must be approved and include the sponsor’s approval date and the Study Director’s dated signature. The QAU monitors independently but does not formally approve the protocol under FDA Part 58.
5. How are protocol amendments documented?
Changes or revisions to an approved protocol must include the reason, be signed and dated by the Study Director, and be kept with the protocol.
6. Is a protocol amendment the same as a deviation?
No. An amendment is a documented change or revision to the approved protocol. A deviation is an event in study conduct that departs from the protocol or procedure and must be assessed and documented under applicable requirements and facility procedures.
7. Can a Study Director delegate study tasks?
Specific work may be assigned to qualified personnel. In OECD multi-site studies, a PI may oversee a defined delegated phase. The Study Director retains overall control of the complete study.
8. What does the QAU do?
The QAU independently monitors the study, inspects it at intervals adequate to assure integrity, documents findings, and reviews the final report against methods and raw data.
9. Does the Study Director sign the final report?
Yes. The final report must be signed and dated by the Study Director.
10. What records must go to the archive?
The Study Director ensures that raw data, documentation, protocols, specimens, and final reports are transferred to the archive during or at the close of the study.